NASDAQ:HSKA

Heska - HSKA Stock Forecast, Price & News

$73.31

+0.39 (+0.53%)

(As of 10/3/2022 05:11 PM ET)

Add

Compare

Today's Range: $71.42
▼
$75.47
50-Day Range: $72.92
▼
$96.95
52-Week Range: $71.42
▼
$269.03

Volume: 114,543 shs
Average Volume: 84,291 shs
Market Capitalization: $793.14 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $184.00

Heska MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 147.9% Upside
$184.00 Price Target
Short Interest: Bearish
11.41% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.89
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.10) to $0.74 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

894th out of 1,093 stocks

Diagnostic Substances Industry

12th out of 17 stocks

3.3

Analyst's Opinion

Consensus Rating
Heska has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $184.00, Heska has a forecasted upside of 147.9% from its current price of $74.22.
Amount of Analyst Coverage
Heska has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
11.41% of the float of Heska has been sold short.
Short Interest Ratio / Days to Cover
Heska has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Heska has recently increased by 64.86%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Heska does not currently pay a dividend.
Dividend Growth
Heska does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HSKA.

2.7

News and Social Media Coverage

News Sentiment
Heska has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Heska this week, compared to 2 articles on an average week.
Search Interest
1 people have searched for HSKA on MarketBeat in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Heska insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.00% of the stock of Heska is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
97.39% of the stock of Heska is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Heska are expected to grow in the coming year, from ($0.10) to $0.74 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Heska is -43.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Heska is -43.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Heska has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Heska (NASDAQ:HSKA) Stock

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was founded in 1988 and is based in Loveland, Colorado.

Receive HSKA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heska and its competitors with MarketBeat's FREE daily newsletter.

HSKA Stock News Headlines

October 2, 2022 | reuters.com

HSKA.OQ - Heska Corp | Stock Price & Latest News | Reuters

September 30, 2022 | finance.yahoo.com

Veterinary Infectious Disease Diagnostics Global Market Report 2022: Featuring Zoetis, IDEXX, Thermo Fisher, Randox & Others - Yahoo Finance

October 3, 2022 | Legacy Research (Affiliate) (Ad)

In 20 years, this little-known trader didn’t have a single losing year…

In his debut video, Market Wizard Larry Benedict reveals how to make all the money you need, in any market, using a single stock. Click here to watch the video and get the name and ticker of the one stock that could put you on the road to financial success.

September 22, 2022 | reuters.com

HSKA.O - Heska Corp | Stock Price & Latest News | Reuters

September 17, 2022 | nasdaq.com

Is There An Opportunity With Heska Corporation's (NASDAQ:HSKA) 33% Undervaluation? - Nasdaq

September 16, 2022 | nasdaq.com

Is There An Opportunity With Heska Corporation's (NASDAQ:HSKA) 33% Undervaluation?

September 12, 2022 | nasdaq.com

Heska To Buy LightDeck For Purchase Price Of $38.7 Mln - Quick Facts

September 12, 2022 | finance.yahoo.com

Heska to Acquire LightDeck Diagnostics to Invest in Manufacturing Capabilities and Accelerate Research and Development Efforts

October 3, 2022 | Legacy Research (Affiliate) (Ad)

In 20 years, this little-known trader didn’t have a single losing year…

September 7, 2022 | businesswire.com

Worldwide Veterinary Care Industry to 2027 - Featuring Ceva Sant Animale, Zoetis, Elanco and Heska Among Others - ResearchAndMarkets.com - Business Wire

September 1, 2022 | finance.yahoo.com

Global Veterinary Immunodiagnostics Market Report to 2027 - by Product Type, Animal Type, Technology, Application, End-user, Distribution Channel and Region - Yahoo Finance

August 26, 2022 | finance.yahoo.com

A Heska Corporation (NASDAQ:HSKA) insider increased their holdings by 0.4% last year - Yahoo Finance

August 26, 2022 | finance.yahoo.com

A Heska Corporation (NASDAQ:HSKA) insider increased their holdings by 0.4% last year

August 26, 2022 | globenewswire.com

Worldwide Veterinary Immunodiagnostics Industry to 2027 - Increased Prevalence of Zoonotic Diseases is Driving Growth - GlobeNewswire

August 22, 2022 | americanbankingnews.com

Piper Sandler Raises Heska (NASDAQ:HSKA) Price Target to $170.00

August 19, 2022 | finance.yahoo.com

Heska Publishes Environmental, Social and Governance (ESG) Factsheet to Share Commitment to Sustainable Responsibilities and Initiatives - Yahoo Finance

August 19, 2022 | finance.yahoo.com

Heska Publishes Environmental, Social and Governance (ESG) Factsheet to Share Commitment to Sustainable Responsibilities and Initiatives

August 17, 2022 | benzinga.com

This Analyst Boosts Price Target On Home Depot Following Strong Earnings, Plus Citigroup Slashes PT On Th - Benzinga

August 16, 2022 | globenewswire.com

Veterinary Infectious Disease Diagnostics Market size worth $ 3.54 Billion, Globally, by 2030 at 8.87% CAGR: Verified Market Research - GlobeNewswire

August 16, 2022 | finance.yahoo.com

Volition Appoints Mickie Henshall as an Independent Director - Yahoo Finance

August 13, 2022 | nasdaq.com

Is Now The Time To Look At Buying Heska Corporation (NASDAQ:HSKA)?

August 10, 2022 | finance.yahoo.com

VolitionRx Limited Announces Second Quarter 2022 Financial Results and Business Update - Yahoo Finance

August 10, 2022 | finance.yahoo.com

Is Heska Corporation (NASDAQ:HSKA) Trading At A 47% Discount?

August 9, 2022 | markets.businessinsider.com

Zacks.com featured highlights include Heska, Tandem Diabetes Care, Credit Suisse Group, Zalando SE and Las Vegas Sands - Markets Insider

August 9, 2022 | latimes.com

Lit festival gathered nation's best Native writers - Los Angeles Times

August 9, 2022 | nasdaq.com

Zacks.com featured highlights include Heska, Tandem Diabetes Care, Credit Suisse Group, Zalando SE and Las Vegas Sands - Nasdaq

August 8, 2022 | finance.yahoo.com

The Global Companion Animal Healthcare Market is expected to grow by $ 9.82 bn during 2022-2026, accelerating at a CAGR of 9.25% during the forecast period - Yahoo Finance

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive HSKA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heska and its competitors with MarketBeat's FREE daily newsletter.

HSKA Company Calendar

Last Earnings: 11/04/2021
Today: 10/03/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HSKA
CUSIP: N/A
CIK: 1038133
Web: www.heska.com
Phone: (970) 493-7272
Fax: 970-619-3003
Employees: 655
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $184.00
High Stock Price Forecast: $250.00
Low Stock Price Forecast: $155.00
Forecasted Upside/Downside: +151.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-1,150,000.00
Net Margins: -6.86%
Pretax Margin: -7.95%
Return on Equity: -1.21%
Return on Assets: -0.87%

Debt

Debt-to-Equity Ratio: 0.24
Current Ratio: 6.92
Quick Ratio: 5.50

Sales & Book Value

Annual Sales: $253.74 million
Price / Sales: 3.13
Cash Flow: $1.05 per share
Price / Cash Flow: 69.62
Book Value: $40.69 per share
Price / Book: 1.80

Miscellaneous

Outstanding Shares: 10,819,000
Free Float: 9,629,000
Market Cap: $793.14 million
Optionable: Not Optionable
Beta: 1.51

Key Executives

Mr. Kevin S. Wilson (Age 50)
CEO, Pres & Director
Comp: $1.84M

Ms. Catherine I. Grassman CPA (Age 46)
Exec. VP & CFO
Comp: $583.3k

Dr. Nancy Wisnewski (Age 59)
Exec. VP & COO
Comp: $581.23k

Mr. Christopher D. Sveen (Age 39)
EVP, Chief Admn. Officer, Gen. Counsel, Corp. Sec. & Pres of Diamond Animal Health
Comp: $536.41k

Mr. Steven M. Eyl (Age 56)
Exec. VP, Chief Commercial Officer & Pres of scil animal care company
Comp: $587.63k

Mr. Jon Aagaard
Director of Investor Relations

Mr. Anthony C. Providenti Jr. (Age 55)
Exec. VP of Corp. Devel.

Ms. Eleanor F. Baker (Age 37)
Exec. VP, MD & COO of scil animal care company

Daniel J. Pollack
VP of Imaging Operations, Treasurer & Assistant Sec.

Laurie E. Peterson
VP of Heska Des Moines

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HSKA Stock - Frequently Asked Questions

Should I buy or sell Heska stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Heska in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HSKA shares.
View HSKA analyst ratings or view top-rated stocks.
What is Heska's stock price forecast for 2022?: 3 Wall Street analysts have issued 1-year price objectives for Heska's stock. Their HSKA share price forecasts range from $155.00 to $250.00. On average, they anticipate the company's share price to reach $184.00 in the next twelve months. This suggests a possible upside of 152.3% from the stock's current price.
View analysts price targets for HSKA or view top-rated stocks among Wall Street analysts.
How have HSKA shares performed in 2022?: Heska's stock was trading at $182.49 on January 1st, 2022. Since then, HSKA shares have decreased by 60.0% and is now trading at $72.92.
View the best growth stocks for 2022 here.
When is Heska's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our HSKA earnings forecast.
How were Heska's earnings last quarter?: Heska Co. (NASDAQ:HSKA) released its quarterly earnings data on Thursday, November, 4th. The medical research company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of $0.04 by $0.23. The medical research company had revenue of $60.24 million for the quarter, compared to analyst estimates of $63.80 million. Heska had a negative net margin of 6.86% and a negative trailing twelve-month return on equity of 1.21%. The company's revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter last year, the company posted ($0.25) earnings per share.
What guidance has Heska issued on next quarter's earnings?: Heska issued an update on its FY 2022 earnings guidance on Tuesday, September, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $273.00 million-$277.00 million, compared to the consensus revenue estimate of $283.56 million.

What is Kevin S. Wilson's approval rating as Heska's CEO?: 5 employees have rated Heska Chief Executive Officer Kevin S. Wilson on Glassdoor.com. Kevin S. Wilson has an approval rating of 57% among the company's employees. This puts Kevin S. Wilson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Heska own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Exelixis (EXEL) and Merck & Co., Inc. (MRK).
What is Heska's stock symbol?: Heska trades on the NASDAQ under the ticker symbol "HSKA."
How do I buy shares of Heska?: Shares of HSKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Heska's stock price today?: One share of HSKA stock can currently be purchased for approximately $72.92.
How much money does Heska make?: Heska (NASDAQ:HSKA) has a market capitalization of $788.92 million and generates $253.74 million in revenue each year. The medical research company earns $-1,150,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis.
How many employees does Heska have?: The company employs 655 workers across the globe.
How can I contact Heska?: Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The official website for the company is www.heska.com. The medical research company can be reached via phone at (970) 493-7272, via email at investorrelations@heska.com, or via fax at 970-619-3003.

This page (NASDAQ:HSKA) was last updated on 10/3/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Heska - HSKA Stock Forecast, Price & News

Heska MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month